Skip to main content
Erschienen in: Wiener klinische Wochenschrift 7-8/2013

01.04.2013 | original article

Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis

verfasst von: Sonja Burgstaller, MD, Michael Fridrik, Sabine Hojas, Thomas Kühr, Heinz Ludwig, Beate Mayrbäurl, Rainer Pöhnl, Michael Pötscher, Ernst Schlögl, Daniela Zauner, Josef Thaler, Heinz Gisslinger

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 7-8/2013

Einloggen, um Zugang zu erhalten

Summary

Current literature provides conflicting evidence regarding the efficacy of lenalidomide in patients with myelofibrosis (MF). The aim of this work was to evaluate the efficacy of lenalidomide in patients with MF treated within a named patient program in Austria. A total of 22 patients with MF were treated with lenalidomide in 7 different centres throughout Austria. Median age of patients was 68 years. Primary MF was present in 13 patients. Eight patients had post-polycythemia vera (post-PV) and 1 post-essential thrombocythemia (post-ET) MF. According to the Dynamic International Prognostic Scoring System (DIPSS), all patients were scored within the intermediate-2 or high-risk group. Approximately one-third of patients were treated with 2 or more prior therapies. The overall response rate according to International Working Group (IWG) criteria was 12.5 %. Efficacy of lenalidomide was moderate in this non-study patient population. Limiting factors seemed to be stage of disease and risk profile of patients included in this analysis.
Literatur
1.
Zurück zum Zitat Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. Proposal and rationale for provision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–7.PubMedCrossRef Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW. Proposal and rationale for provision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–7.PubMedCrossRef
2.
Zurück zum Zitat Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–2901.PubMedCrossRef Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–2901.PubMedCrossRef
3.
Zurück zum Zitat Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J. 2007;13:377–83.PubMedCrossRef Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J. 2007;13:377–83.PubMedCrossRef
4.
Zurück zum Zitat Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levi R, Knoops L, Cervantes F, Vanucchi AM, Barbui T, Barosi G. JAK Inhibition with ruxolitinib verus best available therapy for myelofibrosis. N Engl J Med. 2012;366:778–98.CrossRef Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levi R, Knoops L, Cervantes F, Vanucchi AM, Barbui T, Barosi G. JAK Inhibition with ruxolitinib verus best available therapy for myelofibrosis. N Engl J Med. 2012;366:778–98.CrossRef
5.
Zurück zum Zitat Verstovsek S, Mesa RA, Gotlib J, Levy RS, Grupts V, DipPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MJ, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Ericson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.PubMedCrossRef Verstovsek S, Mesa RA, Gotlib J, Levy RS, Grupts V, DipPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MJ, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Ericson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.PubMedCrossRef
6.
Zurück zum Zitat Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108:1158–64.PubMedCrossRef Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108:1158–64.PubMedCrossRef
7.
Zurück zum Zitat Quintas-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009;27;4760–6.PubMedCrossRef Quintas-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009;27;4760–6.PubMedCrossRef
8.
Zurück zum Zitat Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, Rowe JM, Tefferi A, Tallman MS. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 2010;116:4436–8.PubMedCrossRef Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, Rowe JM, Tefferi A, Tallman MS. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 2010;116:4436–8.PubMedCrossRef
9.
Zurück zum Zitat Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg SA, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108:1497–1503.PubMedCrossRef Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg SA, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108:1497–1503.PubMedCrossRef
10.
Zurück zum Zitat Burgstaller S, Wimmer S, Mayrbäurl B, Hoebling W, Thaler J. Coexistence of primary myelofibrosis and chronic lymphocytic leukaemia—treatment of two different diseases with one agent. Blood Cancer J. 2011;1:e20; doi:10.1038/bcj.2011.18.PubMedCrossRef Burgstaller S, Wimmer S, Mayrbäurl B, Hoebling W, Thaler J. Coexistence of primary myelofibrosis and chronic lymphocytic leukaemia—treatment of two different diseases with one agent. Blood Cancer J. 2011;1:e20; doi:10.1038/bcj.2011.18.PubMedCrossRef
11.
Zurück zum Zitat Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 2011;118:899–902.PubMedCrossRef Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 2011;118:899–902.PubMedCrossRef
Metadaten
Titel
Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis
verfasst von
Sonja Burgstaller, MD
Michael Fridrik
Sabine Hojas
Thomas Kühr
Heinz Ludwig
Beate Mayrbäurl
Rainer Pöhnl
Michael Pötscher
Ernst Schlögl
Daniela Zauner
Josef Thaler
Heinz Gisslinger
Publikationsdatum
01.04.2013
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 7-8/2013
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-013-0345-z

Weitere Artikel der Ausgabe 7-8/2013

Wiener klinische Wochenschrift 7-8/2013 Zur Ausgabe

MUW researcher of the month

Researcher of the Month